Cushing’s syndrome and cardiovascular risk

Czech version

Authors: M. Kršek
Authors‘ workplace: III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in: Kardiol Rev Int Med 2015, 17(2): 161-166
Category: Internal Medicine

Overview

Cushing’s syndrome is a rare disorder characterised by increased autonomous production of cortisol and its exaggerated effects on virtually all tissues in the human body. Therefore its clinical presentation is very complex. One of its main features is significantly increased morbidity and mortality mainly due to cardiovascular disorders. This article reviews basic knowledge about Cushing’s syndrome, pathogenesis of clinical signs, mainly those related to increased cardiovascular risk and basics of diagnosis and treatment of Cushing’s syndrome.

Keywords:
Cushing’s syndrome – hypertension – metabolic syndrome – cardiovascular risk

Sources

1. Cushing HW. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137– 195.

2. Kršek M, Hána V, Vymazal J et al. Cushingův syndrom. Praha: Galén 2006.

3. Ross EJ, Linch DC. Cushing’s syndrome‑ killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2: 646– 649.

4. Nieman LK. Cushing’s syndrome. In: De Groot LJ, Jameson JL. (Eds), Endocrinology. 4th ed. Philadelphia: W. B. Saunders 2001.

5. Urbanic RC, George JM. Cushing’s disease – 18 years’ experience. Medicine (Baltimore) 1981; 60: 14– 24.

6. Soffer LJ, Iannaccone A, Gabrilove JL. Cushing’s syndrome: A study of fifty patients. Am J Med 1961; 300: 129– 135.

7. Pivonello R, Faggiano A, Lombardi G et al. The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am 2005; 34: 327– 339.

8. Tataranni PA, Larson DE, Snitker S et al. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 1996; 271: E317– E325.

9. Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 2007; 292: E654– E667.

10. Hansen KB, Vilsbøll T, Bagger JI et al. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity and high‑calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 2010; 95: 3309– 3317. doi: 10.1210/ jc.2010‑ 0119.

11. Pivonello R, De Leo M, Vitale P et al. Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 2010; 92 (Suppl 1): 77– 81. doi: 10.1159/ 000314319.

12. Greenman Y. Management of dyslipidemia in Cuhsing’s syndrome. Neuroendocrinology 2010; 92 (Suppl 1): 91– 95. doi: 10.1159/ 000314294.

13. Saruta T, Suzuki H, Handa M et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing’s syndrome. J Clin Endocrinol Metab 1986; 62: 275– 279.

14. Mitchell BM, Webb RC. Impaired vasodilatation and nitric oxid synthase activity in glucocorticoid‑induced hypertension. Biol Res Nurs 2002; 4: 16– 21.

15. Arnaldi G, Scandali VM, Trementino L et al. Patophysiology of dyslipidemia in Cushing’s syndrome. Neuroendocrinology 2010; 92 (Suppl 1): 86– 90.

16. Pereira AM, Delgado V, Romijn JA et al. Cardiac dysfunction is reversed upon successful treatment of Cushing’s syndrome. Eur J Endocrinol 2010; 162: 331– 340. doi: 10.1530/ EJE‑ 09‑ 0621.

17. Faggiano A, Pivonello R, Spiezia S et al. Cardiovascular risk factors and common carotid artery calibre and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 2527– 2533.

18. Newell‑Price J. Diagnosis/ differential diagnosis of Cushing‘ s syndrome: a review of best practice. Best Pract Res Clin Endocrinol Metab 2009; 23 (Suppl 1): S5– S14. doi: 10.1016/ S1521‑ 690X(09)70003‑ X.

19. Nieman LK, Biller BM, Findling JW et al. The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526– 1540. doi: 10.1210/ jc.2008‑ 0125.

20. Kršek M, Čáp J, Hána V et al. Doporučení České endokrinologické společnosti pro léčbu Cushingova syndromu v dospělosti. Diabetologie, metabolismus, endokrinologie, výživa 2013; 16: 63– 71.